Stifel lowered the firm’s price target on Crispr Therapeutics (CRSP) to $53 from $59 and keeps a Hold rating on the shares following the ...

Financials climbed across the board in anticipation that a new Trump administration will take a friendlier approach to Wall ...

Stifel Nicolaus analyst Tore Svanberg maintained a Sell rating on Alpha and Omega (AOSL – Research Report) today and set a price target ...

Investing.com -- Shares of Barry Callebaut (SIX: BARN) rose following its results, which showed a stronger-than-expected ...